Fibromyalgia research: where the science is heading
For decades, fibromyalgia was dismissed as a psychological condition or stress response. The lack of a visible marker on standard blood tests meant many clinicians treated it as unexplained, and research funding was limited.
That has started to change, though more slowly than the scale of the illness warrants. Fibromyalgia affects around 2% of the UK population — about 80% of whom are women — and researchers are now investigating several distinct biological mechanisms that could explain the condition.
Is fibromyalgia an autoimmune disease?
One of the most significant developments in fibromyalgia research came in 2021, when a research team from King’s College London, the University of Liverpool, and Sweden’s Karolinska Institute published a study in the Journal of Clinical Investigation. They showed that injecting mice with antibodies from people with fibromyalgia caused the mice to develop fibromyalgia-like symptoms — including increased pain sensitivity, reduced movement, and changes to the small nerve fibres in the skin. Mice injected with antibodies from people without the condition showed no such effects.
The finding suggested that fibromyalgia may be driven, at least in part, by the immune system rather than originating in the brain. If confirmed, it opens a new category of potential treatments — including some that are already used for other autoimmune conditions, such as therapies that reduce antibody levels.
In 2023, the Sir Jules Thorn Charitable Trust awarded £1.7 million to Dr David Andersson at King’s College London to build on this work and develop possible diagnostic tests and therapeutic approaches.
Promising, not proven
The autoimmune hypothesis is a major development, but it has not yet been independently replicated at scale, and not all researchers agree it explains the full symptom picture of fibromyalgia. Some question how antibodies could produce symptoms such as sensitivity to light or smell, which are clearly neurological. This is active research — one of the most hopeful directions in the field, but not yet a settled account of what fibromyalgia is.
Other active research areas
Research into fibromyalgia is not focused on any single mechanism. Several distinct threads are making progress.
Nervous system research
- Small fibre neuropathy. A substantial proportion of people with fibromyalgia show changes to the small nerve fibres in the skin. These findings support the idea that fibromyalgia has a measurable physical basis, although researchers are still working out the relationship between small fibre damage and fibromyalgia symptoms.
- Central sensitisation. Research continues into how the central nervous system processes pain signals in fibromyalgia — and why ordinary sensory input can register as painful.
Gut, metabolism, and biomarkers
- The gut microbiome. Studies consistently find differences in the gut bacteria of people with fibromyalgia. Research teams — notably a group led by Dr Amir Minerbi in Israel and Canada — have linked specific microbiome patterns to fibromyalgia symptoms, though it is not yet clear whether these differences cause the condition, reflect it, or both.
- Biomarker research. Several teams are searching for reliable blood-based markers to support diagnosis. A 2025 Spanish study using proteomic analysis identified candidate protein markers that differed between people with fibromyalgia and healthy controls. Biomarker work is still early, but it is the foundation of the diagnostic tests the condition currently lacks.
These are active research areas, not settled conclusions. Findings are promising but preliminary.
Funding and the wider picture
Fibromyalgia research remains significantly underfunded relative to the number of people affected. In the United States, the American Fibromyalgia Syndrome Association has published critical analyses of National Institutes of Health spending, arguing that a meaningful portion of ostensibly fibromyalgia-related funding is diverted to other conditions or to exercise and behavioural studies of limited clinical value.
In the UK, there is no dedicated public funding stream for fibromyalgia research comparable to the commitments being made for ME/CFS and Long Covid. Progress in the UK has depended largely on individual research teams securing competitive grants and on charities such as Versus Arthritis funding specific projects.
The picture is not uniformly discouraging. The 2023 Sir Jules Thorn award is substantial. Research into Long Covid is beginning to produce findings with possible relevance to fibromyalgia, given the overlap in post-viral symptom patterns. And the volume of fibromyalgia research published internationally has risen steadily over the past decade.
But the field is not yet where it needs to be. There is no dedicated national strategy. No genetic study on the scale of ME/CFS’s DecodeME. And no single funder treating fibromyalgia as a priority condition in its own right rather than a variant of something else.
Is a treatment coming?
A single treatment that resolves fibromyalgia is not an imminent prospect.
The most promising near-term possibility is that antibody-reducing therapies, already used for other autoimmune conditions, may be trialled in fibromyalgia patients. If the autoimmune hypothesis continues to hold up, that could change management meaningfully for some people — but clinical trials take years, and ‘some people’ is doing real work in that sentence. Not every person with fibromyalgia may turn out to have the same underlying mechanism.
The realistic near-term goal is not a cure. It is better diagnostic tools, a clearer understanding of who responds to which existing treatment, and — eventually — a small number of targeted therapies for specific subtypes of the condition.
For people living with fibromyalgia today, that does not change the immediate picture. But for the first time, the field is investigating mechanisms rather than just managing symptoms.